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A B S T R A C T
During the eighteen-year period in »Sestre milosrdnice« University Hospital Center, Zagreb, 271 women with ovarian
tumor was studied. 229 women with ovarian cancer and 42 with borderline tumor. The pathohistological types of tumors
were different. The age of the patients ranged from 20–83 years. In all patients the value of biochemical marker CA125
was determined. The aim of this study was to determine the usefulness of CA125 measurement in different age groups
and in different patohistologycal forms of tumor. CA125 has proven to be positive in 89.1% of women with ovarian cancer
and in 62% with neoplasm of lowmalignant potential. The higher values of CA125 were detected in younger women with
lowmalignant tumor potential. Serous andmetastatic tumor types were also associated with higher values of CA125.
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Introduction
Ovarian cancer has the leading mortality rate among
gynecological tumors and it is a major challenge for
gynecological oncology. The scant symptomatology is the
reason of usually late diagnose and is the leading cause if
death among gynecologycal cancers.
The risk for developing ovarian cancer during woman
life is about 1.5%, and for dieing from it almost 1%1. It is
the fifth cause of all cancer caused mortality in women2.
Ovarian cancer requires extensive surgical treatment,
intensive and often complex therapies. In the last decade,
the incidence of ovarian cancer is growing3. Ovarian tu-
mors are histogenetically, histologically and clinically
very heterogeneous group. The origin of the most com-
mon types is the covering ovary epithelium (more than
90%), specialized reproductive cells and stroma. Epithe-
lial ovarian tumors are the most common type of all ovar-
ian tumors (65–75%) and of all malignant ovarian neo-
plasm (80–90%)4 and are classified as benign, atypical
proliferative (tumors of low malignant potential – LMP)
and malignant tumors5. Histologycally, about 75–80% of
all epithelial tumors are serous type. Less frequent types
are mucinous and endometrioid tumor (10% each) and
light cells cancer, Brenner tumor, and undifferentiated
carcinoma (less than 1% each)1. The incidence of differ-
ent ovary tumors and the best way for distinguishing be-
nign from malignant changes considering anthropologi-
cal parameters (height, weight, body mass index – BMI,
parity, material status, education, age, menopausal sta-
tus, rural versus urban resistance, qualitative dermato-
glyphic traits) have been studied 6,7. For the detection of
ovarian cancer were also examined various diagnostic
methods (X-ray, CT, MR), but the most widely used are:
ultrasound, color doppler and biochemical markers, most
of which CA 125. Also, to effectively discern what kind of
the tumor is present, the different combinations of these
parameters were investigated. The most famous circulat-
ing antigen found in women with ovarian cancer is CA
125, with sensitivity 85–96%8,9. Serum level of this mar-
ker is determined using monoclonal antibodies. About
83% of patients with epithelial ovarian cancer have ele-
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vated level of CA125: 50% in stage I, 60% in stage II, and
over 90% in advanced stages10. CA 125 is used for assess-
ment of the effectiveness of surgical and chemotherapy
treatment11. For some types of the tumor (borderline and
malignant mucinous tumors, serous borderline) sensitiv-
ity of CA 125 is significantly comparing to the invasive
serous cancer. The aim of our study was to determine the
usefulness of marker CA 125 in detecting ovarian cancer
in patohistologycally different tumor types.
Materials and Methods
The survey was conducted in »Sestre milosrdnice«
University Hospital Center, Zagreb, during 18-year pe-
riod. 271 women with ovarian tumor were included (229
with malignant and 42 with LMP). All patients were sur-
gically treated.
The preoperative treatment included determination
of serum marker CA 125 using a monoclonal antibody
(Vitros Immunodiagnostic Products CA 125 II Reagent
Pack, Ortho Clinical Diagnostics). Limit value for CA125
in the laboratory of our Clinic is 35.0U/ml, mean values
<35 U/ml are considered physiological, while those above
that value are considered pathological. After pathophsyo-
logical verification of tumor, patients with malignant tu-
mors and low malignant potential (LMP) were deter-
mined.
Patients were divided regarding age and histopatho-
logic type of the tumor.
In these groups we questioned the marker CA 125
level according to hystological type. In particular, we ex-
amined the incidence of certain types of malignant tu-
mors considering the age and value of CA125. The num-
ber of true positive and false negative Ca 125 results in
specific histopathological types of tumors was calculated.
Interestingly, changed incidence of certain types of tu-
mor over a period of 18 years is found.
Descriptive statistics and frequency distributions we-
re performed. In order to analyse differences in age or
differences in CA 125 values for different tumor type se-
ries of one-way ANOVA were performed. The p-value was
set at 0.05.
Results
During 18 years period in the »Sestre milosrdnice«
University Hospital Center the research involved 271
women, 229 with ovarian cancer and 42 with atypical ep-
ithelial proliferative tumor (LMP). Patients aged be-
tween 20 and 83 years, had 15 different tumor types
patohistologycally verified, (Table 1) and different inci-
dence of certain types during that period (Table 2).
During 1993 the highest incidence had serous carcino-
ma (44.5%). During the next 10 years period (1994–2004)
the highest incidence had endometrioid tumor type. Af-
ter 2004 the occurence of serous carcinoma grew again
and in the past year (2010). Malignant endometriodes tu-
mor type predominates.
The frequency of the three most common histological
types of ovarian cancer in our sample is shown in Figure
1.
The average age of all examined patients was 57.9
years. Due to the patohistologycal result the incidence of
malignant and low malignant potential tumor was differ-
ent according to the age. Patients with malignant disease
were somewhat older (mean 59.3 years, 30–83 years, sd
11.7) (Figure 2).
Patients with LMP were younger (mean 50 years, sd
16.45) (Figure 2).
The age difference is statistically signifficant. (F
(14.256) = 2.49, p<0.01).
CA 125 level did not show statistically significant dif-
ference with respect to pathohistological type of tumor
(F (10.218) = 0.83, p>0.05). The number and percentage
of true positive and false negative results of marker CA
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Fig. 1. The frequency of the three most common histological types
from 1993–2010.
125 with respect to the types of malignant tumors is
shown in Table 3. In group with malignant tumor we can
not abstract the age group in which the percentage of
true positive was significantly higher (Table 4).
The highest percentage of true positive results (over
90%) in patients with serous and metastatic cancers was
observed (with the exception of few histopathological
types insufficient for statistical analysis).
As for LMP tumors, the percentage of true positive re-
sults is far less, only 62% according to our results (Table 5).
Discussion
Ovarian cancer is common disease with high mortal-
ity. Symptoms of the disease occur late, when the disease
is already extended, the treatment options modest and
the results are often poor. For all these reasons there is a
need to optimize early detection techniques, and to ex-
amine the value of existing methods for detecting ovar-
ian cancer.
Tumor markers are molecules occur in blood, urine or
tissue of patients with certain types of cancer in higher
concentrations than normally.
The ideal tumor marker would be: the one that can be
detected in blood, urine or tissue; which is positive only
in patients with malignant disease; whose concentration
coincides with the stage of the disease and response to
treatment; which is secreted in only one tissue and is eas-
ily measured. Unfortunately, no tumor marker has yet
met this ideal. Literature suggests CA 125 level to be
most reliable for distinguishing benign from malignant
ovary12 and borderline tumors. The higher values are
registered in patients with advanced stages of the di-
sease10,13.
Mean values of CA125 were significantly higher in pa-
tients with malignant compared to benign ovary chan-
ges. The cut-off value 35 U / ml is sufficient for diagnose
about 80% of ovarian cancer. CA 125 has proved to be
more reliable variable for identifying malignant tumor in
relation to colored doppler tehnicque in women over 35
years of age.
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TABLE 2
THE FREQUENCY OF HISTOLOGIC TYPE FROM 1993–2010
year
PHD
1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. sum
1993. 3 1 4 1 0 0 0 0 0 0 0 0 0 0 0 9
1994. 4 0 3 0 1 0 0 0 0 0 0 0 0 0 0 8
1995. 4 0 1 0 1 0 0 0 0 0 0 0 0 0 0 6
1996. 7 0 1 4 1 4 1 0 0 0 0 0 0 0 0 18
1997. 5 1 1 1 0 0 1 3 1 1 0 0 0 0 0 14
1998. 6 0 3 2 1 3 0 0 0 0 0 0 0 0 0 15
1999. 5 0 1 4 0 1 0 0 0 0 1 0 0 0 0 12
2000. 4 0 2 0 2 0 1 0 1 0 0 0 0 0 0 10
2001. 3 0 5 1 1 3 1 0 1 0 0 0 0 0 0 15
2002. 5 0 0 0 0 5 1 0 1 0 0 0 0 0 0 12
2003. 9 0 4 0 2 3 0 0 1 0 0 1 0 0 0 20
2004. 4 0 4 0 1 4 1 0 4 0 0 3 1 0 0 22
2005. 7 0 8 0 1 3 0 0 0 0 0 0 0 0 0 19
2006. 5 0 4 1 2 2 0 0 3 0 0 0 0 1 1 19
2007. 5 0 7 0 0 2 3 1 2 0 0 0 0 0 0 20
2008. 5 0 5 1 1 2 1 0 1 0 0 0 0 0 1 17
2009. 2 0 9 1 4 2 0 1 1 0 0 0 0 0 0 20
2010. 5 0 3 1 2 1 1 0 1 0 0 0 0 0 1 15
SUM 88 2 65 17 20 35 11 5 17 1 1 4 1 1 3 271




























Fig. 2. The age of the patients regarding to the patohistologycal
type.
For monitoring the course of illness CA 125 proved to
be a very good marker. Alvarez and colleagues14 state the
literature data about CA 125: good correlation with the
disease with increasing value while progression and low-
ering value while regression of the disease. Other au-
thors15 agree that boosting levels of CA 125 are in very
good correlation with the disease progression.
The most common type is the group of epithelial ovar-
ian cancer (90%). The literature data suggest that 75–85%
of epithelial cancer group are serous type, and rarely
mucinous and endometrioid type (10%)1. Contrary to
these data our eighteen years survey found endometrioid
carcinoma to be the most common histological type
(1994.–2004.). Serous type dominates at the beginning of
the research (1993) and after 2004. during next six years,
after which endometrioid type is the leading type again.
Some authors in their research have also noted that the
incidence of certain histological types of tumor is va-
riabile16. In our study the average age for occurrence of
LMP and malignant types of tumor was 57.9 years,
slightly higher in patients with malignant form (59.3
years), and slightly lower in patients with borderline tu-
mors (50g). Such observations have already been re-
ported in the literature1. Accordingly, our patients with
serous and mucinous borderline tumors were statisti-
cally significantly younger than the other investigated
groups. Since we noted only one woman with endo-
metrioid LMP tumor, conclusion regarding occurence
age is not possible.
For us the most important is an answer to the ques-
tion of how much we can actually rely on the biochemical
marker CA125.
We confirmed the literature results about high reli-
ability of CA 125 marker showing high percentage of true
positive (89.1%) and false negative result (10.9%) in pa-
tients with malignant ovary tumors (cut off value 35
U/ml)17. The highest percentage of true positive results
was found in patients with serous and metastatic malig-
nant tumor types (apart from the group with insufficient
number of patients). Other authors had similar observa-
tions in their research18.
Although we expected stronger response and therefore
maybe higher values of CA125 in younger women we did
not get such results. On the contrary, some authors have
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1. Endometrioid carcinoma 88 13 (14.8) 75 (85.2)
2. Ganulosacellular carcinoma 2 1 (50) 1 (50)
3. Serous carcinoma 65 4 (6.2) 61 (93.8)
4. Mucinous carcinoma 17 4 (23.5) 13 (76.5)
6. Metastatic carcinoma 35 1 (2.9) 34 (97.1)
7. Clarocellular carcinoma 11 2 (18.2) 9 (81.8)
8. Anaplastic carcinoma 5 0 (0) 5 (100)
10. Solid carcinoma 1 0 (0) 1 (100)
11. Mixed mesodermal magninant tumor 1 0 (0) 1 (100)
13. Tubar carcinoma 1 0 (0) 1 (100)
15. Adenocarcinoma mixtum 3 0 (0) 3 (100)
total 229
TABLE 4
THE NUMBER OF TRUE POSITIVE AND FALSE NEGATIVE IN






<30 1 0 1 (100)
31–40 12 2 (16.7) 10 (83.3)
41–50 45 4 (8.9) 41 (91.1)
51–60 65 8 (12.3) 57 (87.7)
61–70 62 5 (8.1) 57 (91.9)
>70 44 6 (13.6) 38 (86.4)
total 229
TABLE 5
THE NUMBER OF TRUE POSITIVE AND FALSE NEGATIVE IN






<30 7 1 (14.3) 6 (85.7)
31–40 5 1 (20) 4 (80)
41–50 10 5 (50) 5 (50)
51–60 9 3 (33.3) 6 (66.7)
61–70 5 3 (60) 2 (40)
>70 6 3 (50) 3 (50)
total 42
noted a higher specificity, sensitivity and the percentage of
true positive results in older, postmenopausal women17.
In our patients with malignant tumors, we can not
single out any particular age group with significantly
higher percentage of true positive results. (Of course, the
group of patients younger than 30 years was excluded
since there was only one patient in that group).
As for tumors of low malignant potential, the authors
agree that the percentage of true positive CA 125 value is
far less reliable in relation to malignant tumors19 and its
value depends on the stage of the disease. Our results on
42 patients with borderline tumors show only 62% true
positive values (Table 5).
It should be noted that two groups with youngest pa-
tients have a higher percentage of true positive results
but since we have small number of such patients the dif-
ference regarding age can not be statistically confirmed.
We believe that our observation will be statistically con-
firmed in further research.
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PREPOZNAVANJE RAKA JAJNIKA ODRE\IVANJEM CA 125 KOD RAZLI^ITIH
PATOHISTOLO[KIH TIPOVA TUMORA S OBZIROM NA DOB
S A @ E T A K
Tijekom 18-godi{njeg perioda u Klini~kom bolni~kom centru »Sestre milosrdnice« u Zagrebu ispitana je 271 `ena sa
tumorom jajnika od ~ega ih je kod 229 dijagnosticiran karcinom jajnika,a kod 42 tumor niskog zlo}udnog potencijala
(»borderline« tumor). Patohistolo{ki tipovi tumora su razli~iti. Uklju~ene su ispitanice od 20–83 godina starosti. Kod
svih pacjentica odre|en je tumorski marker CA 125. Cilj istra`ivanja bio je odrediti korisnost mjerenja markera CA 125
u razli~itim dobnim skupinama i razli~itim patohistolo{kim tipovima tumora. U zaklju~ku: CA125 je pozitivan u 89,1%
`ena sa karcinomom jajnika i u 62% `ena sa neoplazmom nisklog malignog potencijala. Vi{e vrijednosti CA125 na|ene
su kod mla|ih `ena sa neoplazmom niskog malignog potencijala. Serozni i metastatski tumori su povezani sa vi{im
vrijednostima CA125.
H. Solja~i} Vrane{ et al.: Detection of Ovarian Cancer, Coll. Antropol. 36 (2012) 2: 425–429
429
